Trial Profile

Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitors

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Befovacimab (Primary)
Indications Haemophilia A; Haemophilia B
Focus Adverse reactions
Sponsors Bayer

Most Recent Events

01 Sep 2022 Results assessing safety of multiple escalating doses of befovacimab in individuals with severe haemophilia A/B with or without inhibitors, published in the Haemophilia.
05 Nov 2019 Status changed from active, no longer recruiting to discontinued.
05 Nov 2019 This trial has been completed in Austria, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com